Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia

Elliott F. Winton, Vamsi Kota

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Myelofibrosis (MF) is a chronic malignancy of the blood-forming system caused by hyperactivation of JAK2/STAT signaling pathway. Small-molecule inhibitors of JAK2 can variably ameliorate MF-related symptoms caused by chronic inflammation and hepatosplenomegaly. Anemia is a significant problem and adverse prognostic factor in over a third of MF patients and is often worsened by JAK2 inhibitors. The JAK1/2 inhibitor momelotinib unexpectedly resulted in reduction of anemia in MF patients during Phase I/II trials. Current Phase III trials will be the basis for seeking regulatory approval of momelotinib during 2017. Studies to determine how momelotinib improves anemia are underway, potentially leading to expanded momelotinib use and/or development of other targeted therapies for treating anemia in MF and related diseases.

Original languageEnglish (US)
Pages (from-to)395-407
Number of pages13
JournalFuture Oncology
Volume13
Issue number5
DOIs
StatePublished - Feb 1 2017

Fingerprint

Primary Myelofibrosis
Anemia
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Inflammation
Neoplasms

Keywords

  • anemia
  • momelotinib
  • myelofibrosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Momelotinib in myelofibrosis : JAK1/2 inhibitor with a role in treating and understanding the anemia. / Winton, Elliott F.; Kota, Vamsi.

In: Future Oncology, Vol. 13, No. 5, 01.02.2017, p. 395-407.

Research output: Contribution to journalArticle

@article{a9b92287bb214f9380a6d8ea7ed49f98,
title = "Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia",
abstract = "Myelofibrosis (MF) is a chronic malignancy of the blood-forming system caused by hyperactivation of JAK2/STAT signaling pathway. Small-molecule inhibitors of JAK2 can variably ameliorate MF-related symptoms caused by chronic inflammation and hepatosplenomegaly. Anemia is a significant problem and adverse prognostic factor in over a third of MF patients and is often worsened by JAK2 inhibitors. The JAK1/2 inhibitor momelotinib unexpectedly resulted in reduction of anemia in MF patients during Phase I/II trials. Current Phase III trials will be the basis for seeking regulatory approval of momelotinib during 2017. Studies to determine how momelotinib improves anemia are underway, potentially leading to expanded momelotinib use and/or development of other targeted therapies for treating anemia in MF and related diseases.",
keywords = "anemia, momelotinib, myelofibrosis",
author = "Winton, {Elliott F.} and Vamsi Kota",
year = "2017",
month = "2",
day = "1",
doi = "10.2217/fon-2016-0417",
language = "English (US)",
volume = "13",
pages = "395--407",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Momelotinib in myelofibrosis

T2 - JAK1/2 inhibitor with a role in treating and understanding the anemia

AU - Winton, Elliott F.

AU - Kota, Vamsi

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Myelofibrosis (MF) is a chronic malignancy of the blood-forming system caused by hyperactivation of JAK2/STAT signaling pathway. Small-molecule inhibitors of JAK2 can variably ameliorate MF-related symptoms caused by chronic inflammation and hepatosplenomegaly. Anemia is a significant problem and adverse prognostic factor in over a third of MF patients and is often worsened by JAK2 inhibitors. The JAK1/2 inhibitor momelotinib unexpectedly resulted in reduction of anemia in MF patients during Phase I/II trials. Current Phase III trials will be the basis for seeking regulatory approval of momelotinib during 2017. Studies to determine how momelotinib improves anemia are underway, potentially leading to expanded momelotinib use and/or development of other targeted therapies for treating anemia in MF and related diseases.

AB - Myelofibrosis (MF) is a chronic malignancy of the blood-forming system caused by hyperactivation of JAK2/STAT signaling pathway. Small-molecule inhibitors of JAK2 can variably ameliorate MF-related symptoms caused by chronic inflammation and hepatosplenomegaly. Anemia is a significant problem and adverse prognostic factor in over a third of MF patients and is often worsened by JAK2 inhibitors. The JAK1/2 inhibitor momelotinib unexpectedly resulted in reduction of anemia in MF patients during Phase I/II trials. Current Phase III trials will be the basis for seeking regulatory approval of momelotinib during 2017. Studies to determine how momelotinib improves anemia are underway, potentially leading to expanded momelotinib use and/or development of other targeted therapies for treating anemia in MF and related diseases.

KW - anemia

KW - momelotinib

KW - myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=85010066649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010066649&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0417

DO - 10.2217/fon-2016-0417

M3 - Article

C2 - 27785927

AN - SCOPUS:85010066649

VL - 13

SP - 395

EP - 407

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 5

ER -